Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Jan 2, 2014)
  • 8-K (Nov 12, 2013)
  • 8-K (Nov 7, 2013)
  • 8-K (Aug 6, 2013)
  • 8-K (Jul 9, 2013)
  • 8-K (Jun 24, 2013)

 
Other

Santarus 8-K 2005

Documents found in this filing:

  1. 8-K
  2. 8-K
Santarus, Inc. (Form: 8-K)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   September 21, 2005

Santarus, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-50651 33-0734433
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
10590 West Ocean Air Drive, Suite 200, San Diego, California   92130
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   (858) 314-5700

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 7.01 Regulation FD Disclosure.

Santarus, Inc. discloses that the 45-day period following receipt of notice of acceptance by the U.S. Food and Drug Administration of Santarus’ new drug application for Zegerid® Chewable Tablets has expired and that Santarus did not receive notice of a patent infringement suit from AstraZeneca plc and related patent holders concerning Zegerid Chewable Tablets.

For additional information, refer to Santarus’ prior press releases and periodic filings with the Securities and Exchange Commission.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Santarus, Inc.
          
September 21, 2005   By:   /s/ Gerald T. Proehl
       
        Name: Gerald T. Proehl
        Title: President and Chief Executive Officer
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki